Novo Nordisk pre-market jumps as Ozempic shows better cardiovascular protection efficacy than Eli Lilly's old drug
I'm PortAI, I can summarize articles.
Novo Nordisk's stock price rose 6.01% in pre-market trading, marking the largest single-day increase in a month. The reason is that its diabetes drug Ozempic outperformed Eli Lilly's Trulicity in a survey of American patients, with Ozempic patients having a 23% lower risk of heart attack, stroke, or death. The study involved nearly 60,000 diabetes and heart disease patients, and Novo Nordisk announced the results at the European Association for the Study of Diabetes conference
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments